rucaparib,nivolumab
clovis oncology,bms
['ovarian', 'athena-mono']
 dr. rebecca kristeleit from spoke with us about the #asco22 abstract - phase 3 athena-mono #asco late breaker, a randomized, double- study for with ovarian cancer. #oncotwitter 
Produce, Find, and Distribute the latest and highest quality  multimedia to oncologists, hematologists and researchers.